European Physician and Payer Perspectives on Immune-Targeted Agents in Rheumatoid Arthritis

—A Webinar from Decision Resources

Based on our European Physician & Payer Forum report entitled What are European Physician and Payer Expectations for the Uptake of Emerging Oral Immunomodulators in Rheumatoid Arthritis?, Decision Resources is offering this exclusive webinar. Because this presentation will feature major findings, it is ONLY available to purchasers of this report.

Please contact us to learn how you can purchase this report and attend the webinar.

The moderate-to-severe RA population is a lucrative indication for immune-targeted agents owing to its high prevalence and size of the patient population refractory to cheap and generic conventional therapies. However, the barriers to entry are high given the number of effective biologic therapies already marketed; these include five tumor necrosis factor-alpha (TNF-α) inhibitors as well as Bristol-Myers Squibb/Ono Pharmaceutical’s selective costimulation modulator Orencia, Roche’s MabThera (Roche/Biogen Idec Chugai/Zenyaku Kogyo’s B-cell inhibitor Rituxan), and the more recently-launched interleukin-6 (IL-6) inhibitor Actemra/RoActemra from Roche/Chugai. However, two oral agents—Pfizer/Takeda’s tofacitinib and AstraZeneca’s fostamatinib disodium—are set to launch in Europe over the next four years and aim to compete with the TNF-α inhibitors. The introduction of novel formulations for three already-marketed biologics (including subcutaneous formulations of Orencia and RoActemra) has the potential to further fragment the moderate-to-severe RA market.

This report explores physician expectations and payer attitudes regarding emerging novel oral DMARDs tofacitinib and fostamatinib and novel formulations of already-marketed biologics in an environment increasingly focused on cost-containment. The report is based on a survey of 251 rheumatologists in the EU5 and on interviews with 15 European payers and payer-advising key opinion leaders with influence at a national, regional and/or hospital level.

This webinar, presented by Decision Resources Therapeutic Area Director Madhuri Borde, Ph.D., will answer the following questions:

• What funding and reimbursement barriers limit access to biologics? In which lines of therapy do surveyed physicians expect to most commonly prescribe Orencia, MabThera, biosimilar rituximab and RoActemra in 2015? How will physicians prescribe the subcutaneous versus the intravenous formulations of Orencia and Actemra?
• Which patient groups are cited most frequently as being among the top two to whom RoActemra, Orencia and MabThera are prescribed currently, and how will this change in 2015? What have been the main factors restricting physicians’ use of RoActemra?
• What insight do interviewed payers provide on possible reimbursement conditions for novel oral DMARDs and subcutaneous Orencia?
• What efficacy and reimbursement factors would be most instrumental for surveyed rheumatologists to prescribe tofacitinib before a TNF-α inhibitor? Which patient segments are surveyed physicians most likely to prescribe tofacitinib and fostamatinib disodium to by year-end 2015? Which lines of therapy do physicians envision each oral to occupy, and how does this differ by country? In which European markets do market and physician factors suggest more aggressive uptake for tofacitinib?

Dr. Borde will conduct a live Q & A session after the presentation.

Learn more!

European Physician and Payer Perspectives on Immune-Targeted Agents in Rheumatoid Arthritis

January 19, 2012 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 8 New England Executive Park • Burlington, MA 01803

You are receiving this email because you have previously requested information from Decision Resources. You can update your email preferences at any time.

© 2011 Decision Resources, LLC. All rights reserved.